FORGE THERAPEUTICS, INC.   San Diego, CA, USA
forgetherapeutics.com

FG-LPXC LUNG
LPXC INHIBITOR

Direct-Acting Small Molecule Therapeutic
Forge Therapeutics is a privately-held biopharmaceutical company in San Diego, CA developing novel therapeutics targeting metalloenzymes. With its proprietary chemistry approach, Forge’s lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. CARB-X supports two projects in this program, FG-LpxC UTI and FG-LpxC LUNG. Both are novel classes of antibiotics. FG-LpxC UTI is a candidate antibiotic administered intravenously and orally for the treatment of urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilisincluding multi-drug resistant strains. FG-LpxC LUNG is an entirely new class of LpxC inhibitor to treat serious lung infections attributed to Gram-negative bacteria including multi-drug resistant P. aeruginosa

Current Development Stage: Pre-clinical

CARB-X Investment: Initial investment of up to $5.7m with potential option payments up to $5.4m

Initial CARB-X Investment Date: January 1, 2019